Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC1774153446;53447;53448 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
N2AB1610048523;48524;48525 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
N2A1517345742;45743;45744 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
N2B867626251;26252;26253 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
Novex-1880126626;26627;26628 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
Novex-2886826827;26828;26829 chr2:178607467;178607466;178607465chr2:179472194;179472193;179472192
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: R
  • RefSeq wild type transcript codon: AGA
  • RefSeq wild type template codon: TCT
  • Domain: Ig-113
  • Domain position: 65
  • Structural Position: 153
  • Q(SASA): 0.6272
  • Predicted PPI site: I

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
R/G rs1189355872 None 0.959 N 0.525 0.452 0.692629309879 gnomAD-3.1.2 6.58E-06 None None None None I None 0 0 0 0 0 None 0 0 1.47E-05 0 0
R/G rs1189355872 None 0.959 N 0.525 0.452 0.692629309879 gnomAD-4.0.0 6.578E-06 None None None None I None 0 0 None 0 0 None 0 0 1.47167E-05 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
R/A 0.7105 likely_pathogenic 0.6438 pathogenic -0.74 Destabilizing 0.863 D 0.513 neutral None None None None I
R/C 0.2932 likely_benign 0.2483 benign -0.7 Destabilizing 0.999 D 0.546 neutral None None None None I
R/D 0.8646 likely_pathogenic 0.8359 pathogenic 0.031 Stabilizing 0.969 D 0.543 neutral None None None None I
R/E 0.6461 likely_pathogenic 0.6056 pathogenic 0.174 Stabilizing 0.863 D 0.546 neutral None None None None I
R/F 0.723 likely_pathogenic 0.6651 pathogenic -0.423 Destabilizing 0.997 D 0.561 neutral None None None None I
R/G 0.6307 likely_pathogenic 0.549 ambiguous -1.075 Destabilizing 0.959 D 0.525 neutral N 0.488770656 None None I
R/H 0.1728 likely_benign 0.1483 benign -1.324 Destabilizing 0.997 D 0.575 neutral None None None None I
R/I 0.3427 ambiguous 0.3101 benign 0.169 Stabilizing 0.996 D 0.563 neutral N 0.408671683 None None I
R/K 0.1568 likely_benign 0.1434 benign -0.754 Destabilizing 0.021 N 0.204 neutral N 0.387736263 None None I
R/L 0.3692 ambiguous 0.3222 benign 0.169 Stabilizing 0.969 D 0.525 neutral None None None None I
R/M 0.4175 ambiguous 0.3823 ambiguous -0.255 Destabilizing 0.997 D 0.569 neutral None None None None I
R/N 0.7493 likely_pathogenic 0.7007 pathogenic -0.248 Destabilizing 0.969 D 0.55 neutral None None None None I
R/P 0.8928 likely_pathogenic 0.8259 pathogenic -0.112 Destabilizing 0.997 D 0.557 neutral None None None None I
R/Q 0.1833 likely_benign 0.1624 benign -0.354 Destabilizing 0.939 D 0.576 neutral None None None None I
R/S 0.7523 likely_pathogenic 0.6879 pathogenic -1.011 Destabilizing 0.92 D 0.525 neutral N 0.455924125 None None I
R/T 0.4404 ambiguous 0.3823 ambiguous -0.677 Destabilizing 0.959 D 0.538 neutral N 0.421792909 None None I
R/V 0.4996 ambiguous 0.4495 ambiguous -0.112 Destabilizing 0.991 D 0.53 neutral None None None None I
R/W 0.2771 likely_benign 0.2413 benign -0.052 Destabilizing 0.999 D 0.569 neutral None None None None I
R/Y 0.5473 ambiguous 0.4765 ambiguous 0.218 Stabilizing 0.997 D 0.578 neutral None None None None I

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.